Health ❯ Healthcare

Drug Development

Clinical Trials Clinical Research Regulatory Affairs FDA Approval Regulatory Approval Pharmaceuticals Therapeutics Combination Therapy FDA Regulations Oncology

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

The once-daily peptide offers biologic-like efficacy without injections.

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Immutep Halts Phase III Lung Cancer Trial After Futility Call as Shares Crash

FDA Warns Novo Nordisk Over Missed Reporting of Serious Semaglutide and GLP-1 Adverse Events

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

uniQure Soars 36% After FDA Biologics Chief Vinay Prasad Announces April Exit

FDA Approves Sotyktu for Active Psoriatic Arthritis as First TYK2 Inhibitor

Single Daily Bictegravir–Lenacapavir Pill Matches Complex HIV Regimens in Phase III

FDA Proposes ‘Plausible Mechanism’ Pathway for Individualized Rare-Disease Therapies

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Perceptive Advisors Makes Praxis Its Largest Holding After Disclosing Big Q4 Buy

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

FDA Sets Single-Study Default for New Drug Approvals

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

FDA Rejects Filing of Moderna’s mRNA Flu Vaccine Over Comparator Dispute

‘Dancing Molecules’ Therapy Regenerates Nerves in Advanced Human Spinal Cord Organoids

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise